News | June 13, 2023
Pfizer and GSK to battle for share of new RSV vaccine market, says GlobalData
Pfizer is likely to show GSK significant competition
Pfizer is likely to show GSK significant competition
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
Subscribe To Our Newsletter & Stay Updated
